NDC 65862-194OTC monographFDA DRUG FOR FURTHER PROCESSING

Generic formulation

Active substance: Fluoxetine Hydrochloride

FDA labeler: Aurobindo Pharma Limited

20 formulations • 34 package configurations
All 54 registered NDCs — click to copy
In one line

Generic formulation (Fluoxetine Hydrochloride) NDC 65862-194 converts to 65862-0194-22 for billing. It is dispensed by a pharmacy and billed directly on the NDC — no HCPCS J-code is required.

FDA Approval & Market Entry Timeline

Official openFDA & DailyMed regulatory registration sequence
Listing: 65862-194 Verified
1. Initial Approval
2023
First U.S. FDA clearance for Fluoxetine Hydrochloride
2. FDA Application
DRUG FOR FURTHER PROCESSING
Regulatory pathway: DRUG FOR FURTHER PROCESSING
3. Market Entry Date
Jan 31, 2008
First commercial NDC distribution & launch date
4. Regulatory Status
Active Commercial Listing
Registration valid through Dec 31, 2026
Billing & reimbursement crosswalk

NDC • HCPCS Level II • CPT administration

Reimbursement channel
NDC direct
Oral / Topical formulation billed directly via 11-Digit NDC (No HCPCS J-Code required).
Standard pharmacy claim — no J-Code required
11-digit HIPAA NDC
65862-0194-22
Zero-padded 5-4-2 format
Standard conversion
CPT administration code
Self-Administered (Oral)
Dispensed via retail/mail pharmacy. No clinical administration procedure (CPT) required.
UB-04 revenue code
Rev 0250
0250 (General Pharmacy)
Qualifier: UN
Always verify NDC package code, billable multiplier, and invoice qualifier with specific payer guidelines before claim filing.
Complete drug registry

All registered strengths & packaging

Every registered strength and package for Generic formulation, with 10-digit and 11-digit NDC formats
Formulation / rolePackage NDCProduct NDC11-digit HIPAAPackaging detailCopy
20 mg/5mL70954-600-1070954-60070954-0600-10120 mL in 1 BOTTLE, PLASTIC (70954-600-10)
60 mg/151672-5306-251672-530651672-5306-02500 TABLET, FILM COATED in 1 BOTTLE (51672-5306-2)
60 mg/151672-5306-651672-530651672-5306-0630 TABLET, FILM COATED in 1 BOTTLE (51672-5306-6)
20 mg/5mL0832-6032-120832-603200832-6032-121 BOTTLE in 1 CARTON (0832-6032-12) / 120 mL in 1 BOTTLE
20 mg/163629-2200-163629-220063629-2200-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-2200-1)
10 mg/163629-8989-163629-898963629-8989-0160 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-8989-1)
10 mg/163629-8989-263629-898963629-8989-0290 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-8989-2)
20 mg/163629-8990-163629-899063629-8990-0160 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-8990-1)
20 mg/163629-8990-263629-899063629-8990-0290 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-8990-2)
10 mg/149884-335-0149884-33549884-0335-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (49884-335-01)
10 mg/149884-335-1149884-33549884-0335-1130 TABLET, COATED in 1 BOTTLE, PLASTIC (49884-335-11)
20 mg/149884-336-0149884-33649884-0336-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (49884-336-01)
20 mg/149884-336-1149884-33649884-0336-1130 TABLET, COATED in 1 BOTTLE, PLASTIC (49884-336-11)
10 mg/146708-242-3046708-24246708-0242-3030 TABLET, FILM COATED in 1 BOTTLE (46708-242-30)
10 mg/146708-242-3146708-24246708-0242-31100 TABLET, FILM COATED in 1 BOTTLE (46708-242-31)
10 mg/146708-242-9146708-24246708-0242-911000 TABLET, FILM COATED in 1 BOTTLE (46708-242-91)
20 mg/146708-243-3046708-24346708-0243-3030 TABLET, FILM COATED in 1 BOTTLE (46708-243-30)
20 mg/146708-243-3146708-24346708-0243-31100 TABLET, FILM COATED in 1 BOTTLE (46708-243-31)
20 mg/146708-243-9146708-24346708-0243-911000 TABLET, FILM COATED in 1 BOTTLE (46708-243-91)
90 mg/155111-284-4855111-28455111-0284-481 BLISTER PACK in 1 CARTON (55111-284-48) / 4 CAPSULE, DELAYED RELEASE PELLETS in 1 BLISTER PACK
60 mg/116714-114-0116714-11416714-0114-0130 TABLET, FILM COATED in 1 BOTTLE (16714-114-01)
10 mg/172162-1494-172162-149472162-1494-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (72162-1494-1)
10 mg/172162-1494-372162-149472162-1494-0330 TABLET, COATED in 1 BOTTLE, PLASTIC (72162-1494-3)
20 mg/172162-1495-172162-149572162-1495-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (72162-1495-1)
20 mg/172162-1495-372162-149572162-1495-0330 TABLET, COATED in 1 BOTTLE, PLASTIC (72162-1495-3)
10 mg/163629-2197-163629-219763629-2197-0130 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-2197-1)
10 mg/163629-2198-163629-219863629-2198-01100 TABLET, COATED in 1 BOTTLE, PLASTIC (63629-2198-1)
60 mg/168180-997-0668180-99768180-0997-0630 TABLET in 1 BOTTLE (68180-997-06)
10 mg/168180-998-0168180-99868180-0998-01100 TABLET in 1 BOTTLE (68180-998-01)
10 mg/168180-998-0668180-99868180-0998-0630 TABLET in 1 BOTTLE (68180-998-06)
20 mg/168180-999-0168180-99968180-0999-01100 TABLET in 1 BOTTLE (68180-999-01)
20 mg/168180-999-0668180-99968180-0999-0630 TABLET in 1 BOTTLE (68180-999-06)
60 mg/143598-632-0143598-63243598-0632-01100 TABLET, FILM COATED in 1 BOTTLE (43598-632-01)
60 mg/143598-632-3043598-63243598-0632-3030 TABLET, FILM COATED in 1 BOTTLE (43598-632-30)
FDA drug label

Prescribing information

Taken from the manufacturer's FDA Structured Product Labeling submission. This is the label as filed, not a summary. Initial U.S. approval: 2023.

Highlights

These highlights do not include all the information needed to use Generic formulation safely and effectively. The full sections follow.

Indications and usage
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: • Individuals 60 years of age and older. • Individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Limitations of Use: AREXVY is not for use in pregnant individuals.
Dosage and administration
For intramuscular use only. • After reconstitution, a single dose of AREXVY is either 0.5 mL (vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation). • Supplied as two presentations: (1) Vial of Lyophilized Antigen Component reconstituted with accompanying Adjuvant Suspension Component vial; (2) Vial of Lyophilized Antigen Component reconstituted with accompanying prefilled syringe of Adjuvant Suspension Component.
Dosage forms and strengths
For injectable suspension: Single dose after reconstitution is 0.5 mL (vial/vial) or approximately 0.5 mL (vial/prefilled syringe).
Contraindications
History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.
Warnings and precautions
• Guillain-Barré Syndrome: Postmarketing observational study suggests an increased risk of Guillain-Barré syndrome during the 42 days following vaccination. • Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. • Syncope: Syncope (fainting) may occur; procedures should be in place to avoid injury from falling. • Altered Immunocompetence: Immunocompromised persons may have a diminished immune response.
Adverse reactions
• Most commonly reported adverse reactions (≥10%) in adults ≥60 years: injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%). • In adults 50–59 years: injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%). • In adults 18–49 years: injection site pain (76.0%), myalgia (59.9%), fatigue (59.6%), headache (43.6%), and arthralgia (28.3%).
13 Label Sections
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: • Individuals 60 years of age and older. • Individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Limitations of Use: AREXVY is not for use in pregnant individuals [see Use in Specific Populations (8.1)].
2.1 Dose and Schedule After reconstitution, a single dose of AREXVY is either 0.5 mL (vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation). 2.2 Preparation & Reconstitution Instructions AREXVY is supplied in two presentations that must be combined prior to administration: • Vial and Vial Presentation: Reconstitute the Lyophilized Antigen Component (sterile white powder) with the accompanying Adjuvant Suspension Component (opalescent, colorless to pale brownish liquid). Use only the supplied Adjuvant Suspension Component for reconstitution. Withdraw entire contents of adjuvant vial and slowly transfer into antigen powder vial. Gently swirl until completely dissolved. • Vial and Prefilled Syringe Presentation: Reconstitute the Lyophilized Antigen Component vial with the accompanying prefilled syringe of Adjuvant Suspension Component. Slowly transfer entire contents into antigen vial and gently swirl until powder dissolves. 2.3 Administration For intramuscular (IM) injection only, preferably in the deltoid region. After reconstitution, administer AREXVY immediately or store protected from light in the refrigerator between 2°C and 8°C (36°F to 46°F) or at room temperature [up to 25°C (77°F)] and use within 4 hours. Discard reconstituted vaccine if not used within 4 hours.
For injectable suspension. • For the vial and vial presentation, a single dose after reconstitution is 0.5 mL. • For the vial and prefilled syringe presentation, a single dose after reconstitution is approximately 0.5 mL.
Do not administer AREXVY to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of AREXVY [see Description (11)].
5.1 Guillain-Barré Syndrome The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY [see Adverse Reactions (6.2)]. 5.2 Preventing and Managing Allergic Reactions Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY. 5.3 Syncope Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting. 5.4 Altered Immunocompetence Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY.
6.1 Clinical Trials Experience The safety of AREXVY was evaluated in over 17,879 vaccine recipients in multi-center clinical trials (Study 1: NCT04886596 in 24,966 participants). Most Commonly Reported Solicited Adverse Reactions: • Adults ≥60 years: Injection site pain (60.9%), Fatigue (33.6%), Myalgia (28.9%), Headache (27.2%), Arthralgia (18.1%), Erythema (7.5%), Swelling (5.5%), Fever (2.0%). • Adults 50–59 years: Injection site pain (75.8%), Fatigue (39.8%), Myalgia (35.6%), Headache (31.7%), Arthralgia (23.4%), Erythema (13.2%), Swelling (10.4%). • Adults 18–49 years: Injection site pain (76.0%), Myalgia (59.9%), Fatigue (59.6%), Headache (43.6%), Arthralgia (28.3%). 6.2 Postmarketing Experience Postmarketing surveillance identified cases of Guillain-Barré syndrome and acute hypersensitivity reactions following administration.
AREXVY is supplied as: • Outer Carton Kit (58160-848-11): 1 vial of Lyophilized Antigen Component (58160-723-03) and 1 vial of Adjuvant Suspension Component (58160-744-03). • Outer Carton Kit (58160-894-15): 1 vial of Lyophilized Antigen Component (58160-719-03) and 1 prefilled syringe of Adjuvant Suspension Component (58160-749-07). • Outer Carton Kit (58160-882-12): 1 vial of Lyophilized Antigen Component (58160-719-03) and 1 prefilled syringe of Adjuvant Suspension Component (58160-749-07). Storage before Reconstitution: Store in refrigerator between 2°C and 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Discard if frozen. Storage after Reconstitution: Use immediately or store in refrigerator at 2°C to 8°C or room temperature up to 25°C (77°F) for up to 4 hours.
Terms used here11-digit NDCPackage NDCN4 qualifier
Search more NDCs & medical codes